View
Page
AlphaValue's published a note on AstraZeneca, out this morning on Research Tree: "AstraZeneca’s Q1 results came in behind our expectations with product sales growth of 1% to $5.6bn. Externalisation revenue (+78%) contributed $550m, leading to group sales of $6.1bn (+5%). NB All growth numbers at CER unless specific otherwise. Currency had a negative impact of 4% on group sales, which ended at 1% growth yoy. Higher-than-expected R&D spend (+11%) was offset to some extent by effective cost containment at COGS (-19%) and SG&A (-8%), culminating in reported operating profit of $1bn (+17%). Core operating..."
Latest from the Community...
Latest from the Community...
Latest from the Community...